NasdaqCM:PVLABiotechs
Palvella Hire Highlights QTORIN Launch Plans And Deep Rare Skin Focus
Palvella Therapeutics (NasdaqCM:PVLA) has appointed Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services.
McDonough has extensive experience launching and commercializing therapies for rare skin diseases, including work on VYJUVEK®.
The appointment is intended to support Palvella’s commercial readiness as QTORIN™ rapamycin advances through late-stage trials.
For investors watching rare disease drug developers, Palvella Therapeutics sits at the intersection of...